Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERGENE: Phase 3 open-label systemic gene therapy SRP-9003 in LGMD2E/R4
2022-503112-17-00Phase 3Authorised
- Sponsor
- Sarepta Therapeutics
- Start
- Jun 2024
- Modality
- Gene Therapies
- Countries
- 7
01
Overview
Phase 3, open-label trial of bidridistrogene xeboparvovec in limb-girdle muscular dystrophy type 2E (LGMD2E) (2 cohorts), sponsored by Sarepta Therapeutics. Planned start Jun 2024; status: authorised.
02
Drugs
bidridistrogene xeboparvovec
03
Conditions
limb-girdle muscular dystrophy type 2E (LGMD2E)
Beyond the preview
Go deeper on 2022-503112-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503112-17-00.